This week we're looking at a long idea in the Pharma space.

From the desk of Steve Strazza @Sstrazza.

Welcome to our "Under The Hood" column for the week ended September 25, 2020.

What we do is analyze the most popular stocks during the week and find opportunities to either join in and ride these momentum names higher, or fade the crowd and bet against them.

We use a variety of sources to generate the list of most popular names. There are so many new data sources available that all we need to do is organize and curate them in a way that shows us exactly what we want: A list of stocks that are seeing an unusual increase in investor interest.

Whether we're measuring increasing interest based on large institutional purchases, unusual options activity, or simply our proprietary lists of trending tickers... there is a lot of overlap.

The bottom line is there are a million ways to skin this cat. Relying on our entire arsenal of data makes us confident that we're producing the best list each week and gives us more optionality in terms of finding the most favorable trade setups for our clients.

I got a last minute invite to pop on BNN Bloomberg yesterday to chat about the ongoing uptrend in the stock market. While we've seen some stocks and sectors correcting this month, others have held up very well. We want to focus on the ones that did NOT correct, or barely corrected, and are already pressing up against new highs.

With most Indexes in more of a messy range, our focus is on the individual equities.

Here's my interview in full:

(Premium Members can download our "2 to 100 Club" Report & Trade Ideas)

From the desk of Tom Bruni @BruniCharting

In June we outlined that the "Reflation Trade" indicators we track had picked up significantly after reaching levels of long-term support in March.

Since then that thesis has played out and we've been taking advantage of it in Metals, cyclical stock market sectors like Materials and Industrials, and even Agricultural Commodities which managed to break out.

But...after a nice run many of these assets and intermarket relationships have pulled back over the last month or so...begging the question "is the reflation thesis over?"

Luckily for us, we only need one chart to discuss what's happening and how we're approaching it.

The way I learned it is that, "Sector Rotation Is The Lifeblood Of A Bull Market".

But what does that mean exactly? Why does it matter? Why should we care?

All great questions, so I invited my friend Todd Sohn from Strategas and our very own Steve Strazza to discuss this important topic.

What sort of rotation are we seeing today?

Here is Part 1 of our discussion:

From the desk of Steve Strazza @Sstrazza

At the beginning of each week, we publish performance tables for a variety of different asset classes and categories along with commentary on each.

Looking at the past helps put the future into context. In this post, we review the relative strength trends at play and preview some of the things we're watching in order to profit in the weeks and months ahead.

Our last RPP report took a deep look at the damage endured by the most important assets in the world during the recent selloff.

We held this report back a few days this week because the S&P just broke beneath our risk level and was in correction territory, down roughly 10% from its highs intraday on Monday. We wanted to see how things would shake out, and we're glad we did. Let's talk about it.

Since late August we've been discussing the slow, but steady growth in the number of bearish data points pertaining to Indian Equities.

This week we got another one, with a failed breakout in the Nifty Small-Cap Index. Let's take a look at what has happened, what it means, and how we're approaching it.

Here's the Nifty Small-Cap 100 Index chart we shared with members in our Sunday evening post discussing three charts for the week ahead. What we noted was that it was the only major nifty index to make new marginal highs last week, while the Nifty 50, Nifty, Nifty Next 50, and Mid-Cap 100 all made lower highs.

This week on the show, Strazza and I chat with Howard Lindzon as we continue thinking through our "2 to 100" List and how to best set our parameters. Remember, we're looking for the next $100 Billion companies.

We already have industry filters, momentum & relative strength, market capitalization and now we're working in some social sentiment to really give this list some juice. These things are always a work in progress, so I hope this gives you some insight as to how we think through our ideas and have a little fun along the way.

Here is our conversation in full:

From the desk of Steve Strazza @Sstrazza.

Welcome to our "Under The Hood" column for the week ended September 18, 2020.

What we do is analyze the most popular stocks during the week and find opportunities to either join in and ride these momentum names higher, or fade the crowd and bet against them.

We use a variety of sources to generate the list of most popular names. There are so many new data sources available that all we need to do is organize and curate them in a way that shows us exactly what we want: A list of stocks that are seeing an unusual increase in investor interest.

Whether we're measuring increasing interest based on large institutional purchases, unusual options activity, or simply our proprietary lists of trending tickers... there is a lot of overlap.

The bottom line is there are a million ways to skin this cat. Relying on our entire arsenal of data makes us confident that we're producing the best list each week and gives us more optionality in terms of finding the most favorable trade setups for our clients.

This week we're looking at a long idea in the Pharma space.

Everyone is used to complaining about how large-cap tech stocks are the leaders of this market.

I think there could be something new for them complain about.

You see, last time the Russell 2000 Small-cap Index was at these levels relative to the Large-cap Nasdaq 100 Index, Small-cap stocks went on a historic run, particularly relative to those large-caps.

It started exactly 20 years ago, from the exact price we're at today.

Here's what that looks like:

Earlier this month Meb Faber invited me on to his podcast. I really enjoy doing these, especially when they're a bit outside of the Technical community. While Meb is definitely "one of us", in terms of how he views markets, his audience includes people who might not be as informed about technical analysis and its benefits.

This is where I can try my best to do my part to spread the good word. In this conversation we talked about all sort of things from skiing, to markets, to life.

This was a lot of fun. Enjoy!